Abstract
The expression of CYP27B1 or vitamin D 1α-hydroxylase (1α-OHase) and CYP24A1 in specific tissues may act as the central part between 25-hydroxyvitamin D [25(OH)D] serum levels and the anticancer effects of1α,25-dihydroxyvitamin D [1α,25(OH)2D3],alternative splicing of these enzymes may affect their biological functions. Here, we describe the expression of CYP24A1 and its splicing variants detected in breast cells and tissues.
Manifestation of CYP24A1 mRNA was measured by RT-PCR followed by western blot analysis for protein expression.
In MCF-7 cells, the expression of CYP24A1 protein was reduced by about 57% compared to MCF-10F cells. Western blot analysis revealed a signal band at 56 kDa, with additional bands detected at 42 and 44 kDa.
The expression of CYP24A1 mRNA was reduced by about 58% in breast cancer tissues. We found only one signal in the benign tissues at 56 kDa in western blot, whereas in malignant tissue, an additional band was detected at 40kDa.
Our results suggest that alternative splicing of CYP24A1 may lead to a catalytically dysfunctional enzyme.
Keywords: Vitamin D3, 24-hydroxylase, splicing variants, MCF-7, MCF-10, breast tissue.
Anti-Cancer Agents in Medicinal Chemistry
Title:Implication of CYP24A1 Splicing in Breast Cancer
Volume: 14 Issue: 1
Author(s): Chimi Scheible, Marc Thill, Sascha Baum, Erich Solomayer and Michael Friedrich
Affiliation:
Keywords: Vitamin D3, 24-hydroxylase, splicing variants, MCF-7, MCF-10, breast tissue.
Abstract: The expression of CYP27B1 or vitamin D 1α-hydroxylase (1α-OHase) and CYP24A1 in specific tissues may act as the central part between 25-hydroxyvitamin D [25(OH)D] serum levels and the anticancer effects of1α,25-dihydroxyvitamin D [1α,25(OH)2D3],alternative splicing of these enzymes may affect their biological functions. Here, we describe the expression of CYP24A1 and its splicing variants detected in breast cells and tissues.
Manifestation of CYP24A1 mRNA was measured by RT-PCR followed by western blot analysis for protein expression.
In MCF-7 cells, the expression of CYP24A1 protein was reduced by about 57% compared to MCF-10F cells. Western blot analysis revealed a signal band at 56 kDa, with additional bands detected at 42 and 44 kDa.
The expression of CYP24A1 mRNA was reduced by about 58% in breast cancer tissues. We found only one signal in the benign tissues at 56 kDa in western blot, whereas in malignant tissue, an additional band was detected at 40kDa.
Our results suggest that alternative splicing of CYP24A1 may lead to a catalytically dysfunctional enzyme.
Export Options
About this article
Cite this article as:
Scheible Chimi, Thill Marc, Baum Sascha, Solomayer Erich and Friedrich Michael, Implication of CYP24A1 Splicing in Breast Cancer, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/18715206113139990311
DOI https://dx.doi.org/10.2174/18715206113139990311 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Evolving Drug Targets in DNA Base Excision Repair for Cancer Therapy (Guest Editor: Srinivasan Madhusudan)]
Current Molecular Pharmacology Evaluation of Fourteen Aurone Derivatives as Potential Anti-Cancer Agents
Current Pharmaceutical Biotechnology Patent Selections
Recent Patents on Cardiovascular Drug Discovery Optimizing Tumor-Reactive γδT Cells for Antibody-Based Cancer Immunotherapy
Current Molecular Medicine Effect of HPMC - E15 LV premium Polymer on Release Profile and Compression Characteristics of Chitosan/ Pectin Colon Targeted Mesalamine Matrix Tablets and in vitro Study on Effect of pH Impact on the Drug Release Profile
Recent Patents on Drug Delivery & Formulation Gene Therapy of Cancer Based on Interleukin 12
Current Gene Therapy Nuclear Medicine: from Photons to Physiology
Current Pharmaceutical Design Diazine Analogues of the Pyridocarbazole Alkaloids
Current Organic Chemistry The Voltammetric Determination of Bisphenol A Content of Polycarbonate Utensils Using a Resin Modified Carbon Paste Electrode
Current Physical Chemistry Dehydroleucodine Induces a TP73-dependent Transcriptional Regulation of Multiple Cell Death Target Genes in Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Breast Cancer in the Personal Genomics Era
Current Genomics Seek and Destroy: The Use of Natural Compounds for Targeting the Molecular Roots of Cancer
Current Drug Targets Targeting the Coagulation Factor Fibrinogen for Arthritis Therapy
Current Pharmaceutical Biotechnology Role of Defensins and Cathelicidin LL37 in Auto-Immune and Auto- Inflammatory Diseases
Current Pharmaceutical Biotechnology Bioavailability Enhancement of Coenzyme Q10: An Extensive Review of Patents
Recent Patents on Drug Delivery & Formulation Promising Anticancer Drug Candidates Based on the 7-methoxychromone Scaffold: Synthesis and Evaluation of Antiproliferative Activity
Letters in Drug Design & Discovery Potential Advantages of Using Synchrotron X-ray Based Techniques in Pediatric Research
Current Medicinal Chemistry Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous
Current Cancer Drug Targets Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View
Current Cancer Drug Targets